REN and diabetes mellitus: This result was consistent with that of the EX-DKD study, the only published study examining home BP with the 12-week administration of esaxerenone in hypertensive patients with diabetes and eGFR 30–60 mL/min/1.73 m2, inadequately controlled with a renin–angiotensin system (RAS) inhibitor or RAS inhibitor plus CCB (ENaK study at EOT, −11.9/ − 6.4 mmHg; EX-DKD study at EOT, −11.6/ − 5.2 mmHg) [36].